Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

No Cover

ACE Inhibitors in Heart Failure: Advancing Clinical Practice

Satellite Symposium, 3rd International Congress on Heart Failure, 'Mechanisms and Management', Geneva, May 1995

Editor(s): Davies M.K. (Birmingham) 
Giles T. (New Orleans, La.) 

Status: available   
Publication year: 1996
Buy this book
Digital Version: CHF 41.00, EUR 38.00, USD 48.00
Print Version: CHF 41.00, EUR 38.00, USD 48.00
The final prices may differ from the prices shown due to specifics of VAT rules, postage and handling.
Order this title

You already have online access to this title. If you would like to buy a personal digital or print copy, please click here.

A thorough discussion of the latest findings
In this special issue, a number of internationally renowned cardiologists discuss key issues regarding current and future approaches to the management of heart failure, with special emphasis on angiotensin-converting enzyme (ACE) inhibitors. One of the articles examines the importance of ventricular remodelling, focusing on a number of different cardiac conditions. Other contributions present recent studies on the role of ACE inhibitors in preventing the progression of heart failure and in treating postmyocardial infarct patients. Consideration is also given to controversial issues, such as the optimal dose for short- and long-acting ACE inhibitors, and their effect on arrhythmias. In addition, the diagnostic methods used in everyday practice as well as the cost-effectiveness of current therapies are evaluated. The findings presented here show that ACE inhibitors are a potent yet cost-effective means not only to treat patients with both symptomatic and asymptomatic left ventricular dysfunction, but also to reduce mortality and to improve the quality of life.